Tellus Therapeutics secures seed funding to develop first treatment for newborns with white matter brain injury

Tellus Therapeutics secures seed funding to develop first treatment for newborns with white matter brain injury

TT-20 has demonstrated an impressive efficacy and safety profile in models of WMI, supporting its potential as a breakthrough candidate to address the unmet medical need in babies born prematurely. TT-20 is derived from a class of naturally-occurring molecules in breast milk, which promote oligodendrocyte differentiation in postnatal neural stem cell populations. The mechanism of action is reparative and independent of the cause of WMI, thereby providing an advantage over neuroprotective approaches that target only injury prevention. Systemic administration of the breast milk-associated compounds rescues perinatal WMI and reverses motor deficits in mice. TT-20 is in late preclinical development having initiated drug product formulation, IND-enabling work and preparation for a pre-IND meeting in the next year.

About TT-20

About Tellus Therapeutics, Inc.

WMI is the most prevalent form of preterm neonatal cerebral injury and is a strong predictor of poor neurologic outcomes in preterm neonates, leading to adverse neurodevelopmental outcomes including cerebral palsy, intellectual disability, and neurosensory impairments. WMI is characterized by diffuse, subtle changes in the white matter (myelin) microenvironment due to global hypomyelination. This disease process is driven by a reduction in the number of oligodendrocyte progenitor cells (OPCs) that can result from postnatal infections that induce systemic inflammation, including necrotizing enterocolitis or spontaneous intestinal perforations. There are currently no FDA-approved treatments for WMI. The exposure of breast-fed newborns to naturally-occurring molecules supports development as a therapeutic for neonates in which safety is paramount.

“We are thrilled to have Xontogeny as a collaborative partner and appreciate their seed investment to develop a pipeline of products with the potential to improve care, outcomes and lives of patients and their families,” said Jason Kralic, President and Chief Executive Officer, Tellus Therapeutics. “The Tellus team is pleased that the Xontogeny team shares our goal of rapidly advancing our technology with efficient capital deployment and a focus on designing and executing a successful development program. This is especially important for the development of TT-20 and pioneering a regulatory path for ‘First-in-Neonates’ programs that leverages advances in clinical tools and regulatory guidance.”

In addition to Jason Kralic as President and Chief Executive Officer, the Tellus management team includes Eric Benner as Chief Scientific Officer, Austin Schwartz as VP of Operations, Jaron Ballentine as VP of Commercial Strategy, and Alex Ruckdaeschel as an Independent Director. The Board of Directors will be comprised of Chairman, Chris Garabedian, CEO of Xontogeny, Fred Callori, SVP of Corporate Development of Xontogeny, Eric Benner and Jason Kralic.

In the United States, one in ten babies is born preterm and at significant risk for brain injury and life-long cognitive and neurological impairments. Neonatal WMI is the most common brain injury leading to neurodevelopmental disability in survivors of preterm birth. Tellus’s lead candidate, TT-20, is derived from a class of molecules found in breast milk, which promote oligodendrocyte differentiation in postnatal neural stem cell populations. The mechanism of action is reparative and independent of the cause of WMI, thereby providing an advantage over neuroprotective approaches that target only injury prevention. Current medical response consists solely of supportive care, as no treatments are currently approved to treat newborns with white matter brain injury. TT-20 has demonstrated an impressive efficacy and safety profile in models of WMI, supporting its potential as a breakthrough candidate to address this unmet medical need in babies born prematurely.

Forward-Looking Statements

This press release contains “forward-looking statements” concerning the development of Tellus Therapeutics, Inc. products, the potential benefits and attributes of such products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Tellus Therapeutics, Inc. undertakes no obligation to update any forward-looking statements for any reason.

Based in Boston, MA, Xontogeny seeks to accelerate the development of life science technologies by providing entrepreneurs with funding options as well as the leadership, strategic guidance and operational support necessary to increase the probability of success in early drug and technology development. Through a differentiated approach, the Xontogeny team partners with founding scientists and entrepreneurs to support their vision while allowing a more efficient development model that benefits company founders and early equity holders. For more information visit www.xontogeny.com.

About Xontogeny, LLC

As a preclinical stage life sciences start-up company, Tellus is focused on planning, funding and executing development programs to demonstrate safety and efficacy of new therapeutic interventions in critically ill newborns. Founded in October 2018, Tellus is translating breakthrough science licensed from Duke University that originated in board-certified neonatologist Eric Benner’s research laboratory in collaboration with Simon Gregory. Dr. Benner’s work identified compounds in breast milk that induce the regeneration of myelin-producing oligodendrocytes and repair WMI in animal models of perinatal brain injury. Tellus’ goal for its lead asset (TT-20) is to provide a treatment for every baby born at risk for brain injury and improve neurodevelopmental outcomes for affected children. For more information, please visit: http://www.tellustherapeutics.com.

The News Highlights

  • Tellus Therapeutics secures seed funding to develop first treatment for newborns with white matter brain injury
  • Check the latest News news updates and information about business, finance and more.
Disclaimer: If you need to edit or update this news from compsmag then kindly contact us Learn more

For Latest News Follow us on Google News


Latest Headlines
  • Show all
  • Trending News
  • Popular By week
Apple’s New IPad Pro Is Its Vision for the Future of the Laptop

The new iPad mini will have a larger screen and no home button

2021 iPad mini: The latest rumors Jon Prosser of Front Page Tech reports that the sixth-generation iPad mini could look like a smaller version of the iPad ...
Streetsboro Prepares to Receive Federal Stimulus Money

Streetsboro Prepares to Receive Federal Stimulus Money

The new fund was created in order to track ARPA funding allocation and use it within Streetsboro. The 2021 act is a $1.9 trillion economic COVID-19 stimulus ...
Lineage Cell Therapeutics Announces Kevin L. Cook to Join as Chief Financial Officer

Lineage Cell Therapeutics Announces Kevin L. Cook to Join as Chief Financial Officer

Source www.businesswire.com Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are ...
Intel Ready to Deliver Its 11th-generation H-series mobile processors

The Intel M.2 Modem Driver “IOSM” Is Queued Before Linux 5.14

This new Intel M.2 Modem driver is called IOSM which in this case stands for IPC over Shared Memory. The driver is summed up as, “The IOSM (IPC over Shared ...
All about Anker Soundcore Life P3 TWS Earbuds

Soundcore’s upcoming Life P3 true wireless earbuds with amazing features

The 11mm composite drivers will reportedly deliver “rich sound” that is enhanced in real-time by Soundcore’s BassUp technology for “big thumping beats.” Each ...
The Dunkirk Foundry Agreement provides a window into GFG's complex financing web

Wheels Up presents corporate travel offer

Source www.businesstravelnews.com Wheels Up SVP Robert Bourrier will lead the offering and will report to Napolitano. “The travel needs of each company are ...
2011 iMac with Maxwell GPU

2011 iMac with Maxwell GPU

I had a 2011 iMac that I upgraded with Quadro M4000M, here is what I noted: Hello everyone, per some request I started this thread as a spin off of the 2011 ...
Podcast: Legislation and Policy as Tools for Healthy People ​​2030

Podcast: Legislation and Policy as Tools for Healthy People ​​2030

Joel Teitelbaum, JD, LLM Angela McGowan, JD, MPH, is a Senior Director at the American Public Health Association and directs the efforts of the Alliance for ...
New York State continues to reduce public health guidelines while Cornell rules remain virtually unchanged

New York State continues to reduce public health guidelines while Cornell rules remain virtually unchanged

As of June 1, over a month after the CDC decided that mask wearing outdoors was no longer required, the University announced that all faculty and staff members ...
Facebook just unleashed a new suite of social-audio apps !

Facebook Messenger Rooms vulnerability defeats Android screen lock protection

A user’s Facebook account could be compromised by inviting them to a Messenger Room, then calling, and answering the call from, the target device, before ...
Show next
Compsmag - Latest News from tech, business and health
Logo